托法替布治疗强直性脊柱炎的II期16周随机安慰剂对照剂量探索研究
这项II期16周多中心随机安慰剂对照剂量探索试验纳入活动性强直性脊柱炎成人患者,比较托法替布2、5、10 mg每日两次与安慰剂的疗效和安全性。主要终点为12周ASAS20应答率,Emax模型预测托法替布10 mg每日两次ASAS20应答率为67.4%,较安慰剂高27.3%。支持性分析显示托法替布5 mg每日两次ASAS20应答率显著高于安慰剂(80.8% vs 41.2%,p<0.001)。
要点
- 托法替布5 mg每日两次ASAS20应答率显著高于安慰剂(80.8% vs 41.2%,p<0.001)。
- Emax模型预测托法替布10 mg每日两次ASAS20应答率为67.4%,较安慰剂高27.3%。
- 不良反应在各治疗组间相似,未发现非预期安全性问题。
核心结论
- 托法替布5和10 mg每日两次在改善活动性强直性脊柱炎成人患者的症状、体征和客观终点方面优于安慰剂。
- 12周安全性特征与其他适应症报告相似。
研究设计与样本
- 16周(12周治疗,4周洗脱)II期多中心剂量探索试验,患者随机分配至安慰剂或托法替布2、5、10 mg每日两次(每组N=51、52、52、52)。
- 主要疗效终点为第12周ASAS20应答率。
主要发现
- Emax模型分析预测托法替布10 mg每日两次ASAS20应答率为67.4%,较安慰剂高27.3%。
- 支持性正态近似分析显示托法替布5 mg每日两次ASAS20应答率显著高于安慰剂(80.8% vs 41.2%,p<0.001)。
- 托法替布2和10 mg每日两次应答率高于安慰剂(分别为51.9%和55.8%),但未达显著。
- 次要终点普遍显示托法替布5和10 mg每日两次改善优于安慰剂;客观终点(包括MRI)显示明确剂量反应。
关键数值与推荐
- 主要疗效终点:第12周ASAS20应答率。
- 托法替布5 mg每日两次ASAS20应答率80.8% vs 安慰剂41.2%(p<0.001)。
- Emax模型预测托法替布10 mg每日两次ASAS20应答率67.4%,较安慰剂高27.3%。
临床怎么用
- 托法替布5和10 mg每日两次可能改善活动性强直性脊柱炎成人患者的症状、体征及客观终点。
- 治疗期间需监测安全性,12周安全性特征与其他适应症报告相似。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare efficacy and safety of various doses of tofacitinib, an oral Janus kinase inhibitor, with placebo in patients with active ankylosing spondylitis (AS, radiographic axial spondyloarthritis). METHODS: In this 16-week (12-week treatment, 4-week washout), phase II, multicentre, dose-ranging trial, adult patients with active AS were randomised (N=51, 52, 52, 52, respectively) to placebo or tofacitinib 2, 5 or 10 mg twice daily. The primary efficacy endpoint was Assessment of SpondyloArthritis International Society 20% improvement (ASAS20) response rate at week 12. Secondary endpoints included objective measures of disease activity, patient-reported outcomes and MRI of sacroiliac joints and spine. Safety was monitored. RESULTS: Emax model analysis of the primary endpoint predicted a tofacitinib 10 mg twice daily ASAS20 response rate of 67.4%, 27.3% higher than placebo. Supportive normal approximation analysis demonstrated tofacitinib 5 mg twice daily ASAS20 response rate significantly higher than placebo (80.8% vs 41.2%; p<0.001); tofacitinib 2 and 10 mg twice daily demonstrated greater response rate than placebo (51.9% and 55.8%, respectively; not significant). Secondary endpoints generally demonstrated greater improvements with tofacitinib 5 and 10 mg twice daily than placebo. Objective (including MRI) endpoints demonstrated clear dose response. Adverse events were similar across treatment groups with no unexpected safety findings. Dose-dependent laboratory outcome changes returned close to baseline by week 16. CONCLUSIONS: Tofacitinib 5 and 10 mg twice daily demonstrated greater clinical efficacy versus placebo in reducing signs, symptoms and objective endpoints of active AS in adult patients with a similar 12-week safety profile as reported in other indications. TRIAL REGISTRATION NUMBER: NCT01786668.
引用
- van der Heijde D, Deodhar A, Wei JC, et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2017. PMID: 28130206. doi:10.1136/annrheumdis-2016-210322
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。